Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2023

(Commission File No. 001-40241)

---

LAVA Therapeutics N.V.

(Translation of registrant’s name into English)

---

Yalelaan 62

3584 CM Utrecht, The Netherlands

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒ Form 40-F  ☐

​

​

​

​

---

LAVA Therapeutics, N.V.

On April 11, 2023, LAVA Therapeutics, N.V. (Company) issued a press release announcing the Company’s financial results for the three months and year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Exhibit 99.1 to this Report on Form 6-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

​

EXHIBIT LIST

Exhibit		Description
99.1	​	Press Release, dated April 11, 2023
​	​	​

​

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​	​	​
​	LAVA Therapeutics, N.V.
​	(Registrant)
​	​	​
Date: April 12, 2023	By:	/s/ Fred Powell
​	Fred Powell
​	Chief Financial Officer

​

---